A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
Clinical trial NCT06112379 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06112379
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-14
- Primary completion
- 2028-11-20
- Enrollment
- 1902
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.